Researchers have found that a reciprocal feedback blockade using trametinib and imatinib may overcome limitations of current therapy targeting KRAS. This approach is being explored as a potential solution to the challenges posed by existing KRAS-targeted treatments. The combination of trametinib and imatinib is showing promise in addressing these limitations.